PMID- 25480344
OWN - NLM
STAT- MEDLINE
DCOM- 20150817
LR  - 20181113
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 7
DP  - 2014 Dec 6
TI  - Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of 
      hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the 
      PARAT trial.
PG  - 880
LID - 10.1186/1756-0500-7-880 [doi]
LID - 880
AB  - BACKGROUND: Hyperkalemia is an infrequent but potentially serious complication of 
      low molecular weight heparin (LMWH) use. While there are a number of trials 
      comparing LMWH to unfractionated heparin (UFH) there is no comparison of the risk 
      with LMWH versus placebo. Aim of the present post-hoc analysis of the PARAT trial 
      was the description of serum potassium levels with certoparin compared to 
      placebo. RESULTS: PARAT was a double-blind, placebo-controlled, randomized trial 
      in patients with coronary artery disease receiving either 8,000 I.U. aXa per day 
      or placebo. Serum potassium was monitored at baseline and at scheduled follow-up 
      visits at 2 and 4-6 weeks and 3 and 4-6 months. Statistical evaluation included 
      paired, two sided t-test for each of the treatment groups to compare baseline and 
      follow-up values. A total of 117 patients (59 certoparin, 58 placebo) were 
      included with a mean age of 59 years and 84.6% male gender. There was a 
      statistically significant increase in serum potassium at two weeks after 
      discharge compared to baseline (p<0.001) in either group which remained elevated 
      throughout the three months treatment phase. Differences between treatment groups 
      were not statistically significant. After treatment discontinuation at the three 
      months' visit serum potassium returned to normal values (p=n.s. vs. baseline) in 
      both groups. Overall 12 out of 59 patients receiving certoparin (20.3%) and 11 
      out of 58 patients receiving placebo (19.0%) experienced hyperkalemia based on 
      threshold of >5.0 mmol/l at any time during the observation. CONCLUSIONS: We 
      conclude that there is no incremental risk of hyperkalemia with certoparin up to 
      8,000 I.U. aXa per day versus placebo in patients with coronary artery disease. 
      The increase in serum potassium values in either group calls for clinical 
      surveillance and the consideration of further risk factors predisposing to 
      hyperkalemia.
FAU - Melzer, Nima
AU  - Melzer N
FAU - Bramlage, Peter
AU  - Bramlage P
AD  - Institut fur Pharmakologie und Praventive Medizin, Menzelstrasse 21, 15831 
      Mahlow, Germany. peter.bramlage@ippmed.de.
FAU - Michaelis, Hans-Christoph
AU  - Michaelis HC
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20141206
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Placebos)
RN  - V72OT3K19I (certoparin)
SB  - IM
MH  - Aged
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Coronary Artery Disease/*complications
MH  - Double-Blind Method
MH  - Female
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Hyperkalemia/*chemically induced
MH  - Male
MH  - Middle Aged
MH  - Placebos
PMC - PMC4307893
EDAT- 2014/12/07 06:00
MHDA- 2015/08/19 06:00
PMCR- 2014/12/06
CRDT- 2014/12/07 06:00
PHST- 2014/06/10 00:00 [received]
PHST- 2014/11/28 00:00 [accepted]
PHST- 2014/12/07 06:00 [entrez]
PHST- 2014/12/07 06:00 [pubmed]
PHST- 2015/08/19 06:00 [medline]
PHST- 2014/12/06 00:00 [pmc-release]
AID - 1756-0500-7-880 [pii]
AID - 3470 [pii]
AID - 10.1186/1756-0500-7-880 [doi]
PST - epublish
SO  - BMC Res Notes. 2014 Dec 6;7:880. doi: 10.1186/1756-0500-7-880.